25 related articles for article (PubMed ID: 18327815)
1. Endometrioid epithelial ovarian cancer : 20 years of prospectively collected data from a single center.
Storey DJ; Rush R; Stewart M; Rye T; Al-Nafussi A; Williams AR; Smyth JF; Gabra H
Cancer; 2008 May; 112(10):2211-20. PubMed ID: 18344211
[TBL] [Abstract][Full Text] [Related]
2. A randomized comparison of triptorelin and tamoxifen as treatment of progressive ovarian cancer.
Jager W; Sauerbrei W; Beck E; Maassen V; Stumpfe M; Meier W; Kuhn W; Janicke F
Anticancer Res; 1995; 15(6B):2639-42. PubMed ID: 8669839
[No Abstract] [Full Text] [Related]
3. A phase II clinical trial of topotecan in Japanese patients with relapsed ovarian carcinoma.
Aoki D; Katsumata N; Nakanishi T; Kigawa J; Fujiwara K; Takehara K; Kamiura S; Hiura M; Hatae M; Sugiyama T; Ochiai K; Noda K
Jpn J Clin Oncol; 2011 Mar; 41(3):320-7. PubMed ID: 20974678
[TBL] [Abstract][Full Text] [Related]
4. [Factors of resistance of ovarian cancer to combined chemotherapy with the use of platinum derivatives].
Bliumenberg AG; Gorbacheva LB; Gorbunova VA; Kozachenko VP; Lankin VZ
Biull Eksp Biol Med; 1996 Dec; 122(12):651-4. PubMed ID: 9280465
[No Abstract] [Full Text] [Related]
5. Phase II clinical study on the GEMOX regimen as second- line therapy for advanced ovarian cancer.
Yuan SF; Zhang LP; Zhu LJ; Chen WJ; Zheng WE; Xiong JP
Asian Pac J Cancer Prev; 2013; 14(6):3949-53. PubMed ID: 23886213
[TBL] [Abstract][Full Text] [Related]
6. Editorial. Endometrioid epithelial ovarian cancer.
Cibull ML; Karabakhtsian RG
Cancer; 2008 May; 112(10):2108-11. PubMed ID: 18327815
[No Abstract] [Full Text] [Related]
7. [Uterine papillary serous carcinoma--a different kind of tumor].
Steinman N; Avni A
Harefuah; 1999 May; 136(10):810-2. PubMed ID: 10955120
[No Abstract] [Full Text] [Related]
8. Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer.
Bowtell DD; Böhm S; Ahmed AA; Aspuria PJ; Bast RC; Beral V; Berek JS; Birrer MJ; Blagden S; Bookman MA; Brenton JD; Chiappinelli KB; Martins FC; Coukos G; Drapkin R; Edmondson R; Fotopoulou C; Gabra H; Galon J; Gourley C; Heong V; Huntsman DG; Iwanicki M; Karlan BY; Kaye A; Lengyel E; Levine DA; Lu KH; McNeish IA; Menon U; Narod SA; Nelson BH; Nephew KP; Pharoah P; Powell DJ; Ramos P; Romero IL; Scott CL; Sood AK; Stronach EA; Balkwill FR
Nat Rev Cancer; 2015 Nov; 15(11):668-79. PubMed ID: 26493647
[TBL] [Abstract][Full Text] [Related]
9. The role of immunohistochemistry in differentiating between peritoneal mesothelioma and ovarian serous carcinoma.
Al-Rawi HJ; Ben-Ghashir NS
Saudi Med J; 2009 Apr; 30(4):571-4. PubMed ID: 19370292
[No Abstract] [Full Text] [Related]
10. [Ovarian and endometrial neoplasms and the use of hormone replacement therapy].
Ivanov S; Ivanov I
Akush Ginekol (Sofiia); 2005; 44(5):45-6. PubMed ID: 16313054
[TBL] [Abstract][Full Text] [Related]
11. [Updates on pathogenesis of ovarian tumors].
Guo XR; Shen DH; Du JR
Zhonghua Bing Li Xue Za Zhi; 2008 Sep; 37(9):627-30. PubMed ID: 19094589
[No Abstract] [Full Text] [Related]
12. The controversies surrounding the management of uterine serous carcinoma.
Munkarah AR
Cancer; 2004 Nov; 101(10):2152-4. PubMed ID: 15389471
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
